The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.
This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab.
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2010 |
| Verlag/Hrsg.: |
BioMed Central Ltd.
|
| Schlagwörter: | Antibodies / Monoclonal / Murine-Derived - therapeutic use / Antirheumatic Agents - therapeutic use / Treatment Outcome / Arthritis / Rheumatoid - drug therapy / Belgium / Female / Humans / Male / Middle Aged / Registries / Severity of Illness Index |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-26526545 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://hdl.handle.net/2078.1/105549 |
